SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as it faces a wave of analyst downgrades and intense investor frustration over its prolonged stock underperformance, despite a low valuation and active share buyback program. While many criticize current management and see it as 'dead money,' a bullish segment argues the fintech giant is significantly undervalued, poised for a rebound as it solidifies its position in digital payments and the evolving 'buy now, pay later' market.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending following recent developments, including Amazon Pharmacy's launch of Novo Nordisk's oral GLP-1 weight loss pill which is notably unavailable on HIMS's platform, compounded by an analyst downgrade citing elevated 2026 investment outlook. This has ignited a split in community sentiment, with many questioning HIMS's competitive moat, while others actively buy the dip, asserting confidence in the company's broader personalized healthcare platform and vertical integration for long-term growth.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is actively trending as its advanced agentic and voice AI technology showcased at a recent major tech conference generated significant buzz, leading to new partnerships in the automotive and robotics sectors. The community is heavily discussing the stock's high short interest, anticipating a potential squeeze, and highlighting its strong revenue growth and strategic position within the expanding AI market.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd (SUGP) is trending as community discussion highlights its ultra-low share float and significant short interest, creating strong speculation for a potential short squeeze. Traders are actively drawing comparisons to past high-volatility runners like SMX, fueled by its presence on the Reg SHO list, high cost to borrow, and anticipation of upcoming earnings and contract news as potential catalysts.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics (ATRA) is trending following a second FDA Complete Response Letter for its EBVALLO cancer therapy, which now cites concerns over clinical trial design despite previously resolved manufacturing issues. The community is expressing significant frustration over the FDA's unexpected change in position and questioning the need for a new trial, especially given the drug's existing approval in Europe.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is trending after announcing preliminary quarterly and full-year results that significantly beat revenue expectations, sparking strong bullish sentiment across the community. Investors are keenly discussing the impressive growth, coupled with high analyst price targets and the potential for a rally driven by the stock's low free float. However, some continue to voice concerns regarding the company's cash reserves and the ongoing risk of dilution.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony is trending amidst escalating geopolitical tensions, particularly concerning critical minerals and China's tightening export restrictions, positioning the company as a crucial domestic supplier for defense. The community is actively discussing its role as the sole North American integrated antimony producer for the U.S. military and anticipating significant government investment to secure national supply chains. Sentiment remains highly bullish, with many seeing the company as undervalued given its strategic importance and expected contract expansions.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending following strong preliminary financial results, which exceeded revenue expectations and highlighted record total contract value with high net revenue retention. This news, driven by significant growth in its diagnostics segment, is fueling community discussion around the company's strategic position in AI-powered oncology and precision medicine. Investors are actively debating the sustainability of its growth trajectory and valuation after substantial recent share appreciation.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax (ABVX) is trending due to heightened speculation surrounding a potential takeover by Eli Lilly and other major pharmaceutical companies, with reports from French media and government sources fueling the buzz. The community is actively discussing an impending bidding war and significant premiums for its promising ulcerative colitis drug, obefazimod, which has demonstrated strong Phase 3 data. This innovative treatment positions Abivax as a highly attractive target in the competitive inflammatory bowel disease market.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio is trending following a significant strategic collaboration for global expansion of its lead oncology therapy. The community is buzzing about the strong commercial performance and impressive clinical data for its core assets, solidifying a "best-in-class" perception and fueling acquisition speculation within an active biotech market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
